Rituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis

Rachel B. Jones

Department of Renal Medicine, Addenbrooke’s Hospital Cambridge, Cambridge, UK

Key Words
Anti-neutrophil cytoplasm antibody-associated vasculitis · Rituximab · Remission

Abstract
The introduction of cyclophosphamide and high-dose glucocorticoids for anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) has allowed a reduction in 1-year mortality from 80% to 10–20%. AAV is now a chronic disease, and greater emphasis has turned to improving treatment-related toxicity, reducing relapses and providing alternative treatments for refractory disease. Rituximab, an anti-CD20 B cell-depleting therapy, has been used for over a decade in patients with AAV. Rituximab offers a significant advance in the treatment of these diseases. It has an established role for remission induction and is now being investigated as a remission maintenance agent. For remission induction, randomised trials have reported similar remission rates with rituximab and cyclophosphamide, and rituximab is now an approved alternative to cyclophosphamide in severe AAV. In clinical practice, rituximab is increasingly used for refractory and relapsing disease. Further remission induction data with rituximab for life-threatening renal and pulmonary disease may be provided by the ongoing PEXIVAS trial (NCT00987389). With standard therapies, 50% of patients with newly diagnosed AAV relapse by 5 years. Relapses are higher still in patients with known relapsing disease. For remission maintenance, treatment trials are comparing repeat rituximab dosing to azathioprine. The MAINRITSAN trial (NCT00748644) included mainly newly diagnosed AAV patients following cyclophosphamide induction therapy. The RITAZAREM trial (NCT01697267) is randomising patients with relapsing disease after rituximab induction therapy. Preliminary results with rituximab maintenance therapy are encouraging, although the optimal dosing regimen and duration has yet to be defined. Other areas for further investigation include remission maintenance therapy requirement after rituximab induction in newly diagnosed AAV, and the role of rituximab in eosinophilic granulomatosis with polyangiitis where no randomised data exists.

© 2014 S. Karger AG, Basel

Introduction

The anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides are autoimmune diseases characterised by a necrotising small vessel vasculitis and ANCA

Biologic Treatment in Glomerular Disease
D. Jayne, Cambridge
V. Tesar, Prague

KARGER © 2014 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/nec

Rachel B. Jones
Department of Renal Medicine
Addenbrooke’s Hospital Cambridge
Cambridge (UK)
E-Mail rbj23@cam.ac.uk
targeting either proteinase 3 or myeloperoxidase. ANCA-associated-vasculitis (AAV) includes three diseases: granulomatosis with polyangiitis (GPA; previously Wegener’s granulomatosis), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA, previously Churg-Strauss syndrome) [1]. Both GPA and MPA are associated with pauci-immune necrotising glomerulonephritis as the most common severe manifestation, which untreated progresses to end-stage renal disease. Due to similarities in disease manifestations and early treatment responses, GPA and MPA are frequently grouped together in therapeutic trials. The key differences between these two diseases are the presence of respiratory tract granuloma in GPA and the association of GPA with proteinase 3-ANCA and MPA with predominantly myeloperoxidase-ANCA (proteinase 3-ANCA being associated with greater relapse risk) [2]. EGPA is usually considered separately in treatment trials. EGPA is differentiated by a peripheral eosinophilia and asthma [1], and compared to GPA and MPA, EGPA has lower rates of ANCA positivity and renal vasculitis. Consequently, evidence for new therapies in AAV tends to rely mainly on experience in GPA and MPA patients.

Since the introduction of cyclophosphamide and high-dose glucocorticoids in the 1970s, AAV has transformed from a disease with 80% mortality [3], into a chronic relapsing and remitting disease. Current outcomes at 5 years are 25% mortality and a 50% relapse rate [2]. Treatment strategies have evolved to 3–6 months of remission induction therapy, followed by 12–24 months of remission maintenance therapy, following which treatment withdrawal is considered [4]. In severe disease with major organ involvement, cyclophosphamide with high-dose glucocorticoids is standard induction therapy. Azathioprine and methotrexate, with low-dose glucocorticoids, are standard remission maintenance agents [5]. Plasma exchange is an adjunctive therapy for remission induction in patients with poor renal function (creatinine >500 μmol/l) [6]. Newer therapies are being investigated in order to further improve disease-related outcomes, e.g. reducing refractory disease, relapse and chronic organ damage. Another important expectation for new treatments is reduced toxicity compared to cyclophosphamide and high-dose glucocorticoids, particularly lower infection, malignancy and infertility risks. Rituximab is a potential alternative to cyclophosphamide and offers a significant advance in the treatment of AAV. This article reviews the current evidence for rituximab as a remission induction and remission maintenance therapy in AAV.

Rationale for a B Cell-Depleting Therapy in AAV

Rituximab is a chimeric monoclonal antibody that binds to CD20, a calcium ion channel, expressed on most B cells, except plasma cells [7]. Rituximab results in rapid B cell depletion using antibody-dependent cell-mediated cytotoxicity, complement-mediated cytotoxicity and apoptotic mechanisms [8]. It was originally approved to treat B cell lymphoma in 1995. The benefit of rituximab in antibody-associated autoimmune diseases, particularly rheumatoid arthritis [9], led to the evaluation of rituximab in AAV.

There is a strong rationale for the use of B cell-targeted therapies in AAV: B cell activation occurs in active AAV [10, 11], ANCA are produced by B cells which are strongly implicated in disease pathogenesis [12, 13], autoreactive B cells are present in granulomatous lesions in GPA [14, 15], and cyclophosphamide suppresses B cell activation and proliferation [16] and is efficacious treatment for AAV. Rituximab appears effective in both ANCA-positive and ANCA-negative AAV [17]. Rituximab likely works through additional mechanisms beyond just the depletion of precursors to ANCA-producing cells.

Remission Induction Therapy for Refractory AAV

The initial experience with rituximab in AAV was in patients with either cyclophosphamide refractory disease or relapsing disease. The first case report was published in 2001 [18]. Subsequent pilot trials [19, 20] and retrospective case series described high remission rates with rituximab (typically 80–100%; e.g. [21–26]). More than 250 cases have now been reported in the literature. One early report described failure to induce remission in patients with severe granulomatous manifestations [27]. However, this study reported short-term outcomes only. Studies with longer follow-up have found rituximab to be effective for both granulomatous and vasculitic disease [17]. Severe granulomatous manifestations such as orbital or meningeal disease typically show slower and less complete response to a first rituximab course. This may be due to incomplete B cell depletion within granulomatous lesions. Subsequent repeat rituximab dosing appears to facilitate full remission in such patients [28].

Initial reports used one of two different rituximab dosing regimens: either four doses of 375 mg/m² body surface area administered once a week for 4 weeks (the original lymphoma dosing regimen) or two doses of 1,000 mg administered 2 weeks apart (the rheumatoid arthritis reg-
Rituximab is increasingly used to treat refractory and relapsing AAV.

**Treatment Trials with Rituximab for Remission Induction in AAV**

Following uncontrolled reports of efficacy with rituximab in refractory AAV, two randomised trials have compared rituximab to cyclophosphamide for remission induction in severe GPA and MPA [33, 34]. The design and major outcomes of both studies are summarised in Table 1. Key differences in the RAVE trial were the inclusion of patients with relapsing as well as newly diagnosed AAV, exclusion of patients with creatinine greater than 354 μmol/l and complete withdrawal of glucocorticoids by 6 months [33]. In contrast, the RITUXVAS trial recruited only patients with newly diagnosed renal AAV (including those with dialysis dependence), used two intravenous doses of cyclophosphamide in the rituximab group and continued low-dose glucocorticoids beyond 6 months [34]. Both trials reported similar remission rates between the cyclophosphamide and rituximab groups. In the RAVE trial, rituximab was associated with superior remission rates in the subgroup of patients with relapsing disease. Following the RAVE trial, rituximab 375 mg/m² administered once a week for 4 weeks gained regulatory approval for remission induction in severe AAV.

Dialysis-dependent patients were excluded from the RAVE trial and were few in number in the RITUXVAS study. Further investigation of rituximab in this important subgroup is therefore required. The ongoing PEXIVAS plasma exchange trial (NCT00987389) is recruiting 500 patients, including those with dialysis dependence. PEXIVAS permits the use of either cyclophosphamide or rituximab for remission induction, so it may expand knowledge of rituximab’s efficacy in this subgroup.

At the final follow-up in the RAVE and RITUXVAS trials, relapse rates were similar between groups [35, 36]. Neither trial used remission maintenance therapy in the rituximab group; both trials used azathioprine maintenance therapy in the cyclophosphamide group. Relapses in rituximab patients occurred after B cell return in all RITUXVAS patients and most RAVE trial patients. Vigilance for relapse is recommended, following B cell return in patients not receiving remission maintenance therapy after a rituximab induction course [36]. It has yet to be determined whether relapses after rituximab in newly diagnosed AAV can be reduced by remission maintenance agents.

**Rituximab as Remission Maintenance Therapy in AAV**

In relapsing and refractory AAV, relapse rates are high after a single rituximab induction course. The average time to relapse is 13 months [17, 30]. Relapses usually, but not always, occur following peripheral B cell return. The timing of relapse in relation to B cell return is imprecise. Some patients relapse at the time of B cell return, some relapse many months later and a minority appear not to relapse at all. This lack of precision likely reflects the inexact relationship between peripheral B cells and tissue B cell activity. B cells have been identified within inflamed tissues in patients relapsing in the absence of peripheral B cells [37].

Following rituximab for relapsing AAV, most investigators have withdrawn concomitant immunosuppressants to reduce toxicity [17, 28, 29]. However, continued use of oral immunosuppressants may help reduce relapses [30]. An alternative remission maintenance strategy, adopted by several investigators, is repeat rituximab dosing during remission. Studies using rituximab as maintenance therapy are summarised in Table 2. No consensus on the optimal maintenance strategy has been achieved. Options include the use of B cells with ANCA to determine the timing of rituximab treatment. Success with this approach was reported by Cartin-Ceba et al. [32], who observed no relapses in patients who met the re-treatment criteria; however,
Table 1. Comparison of the RAVE [33, 35] and the RITUXVAS [34, 36] AAV remission induction trials

<table>
<thead>
<tr>
<th>Aspects of design</th>
<th>RAVE</th>
<th>RITUXVAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall design</td>
<td>Randomised, double blinded, non-inferiority, 18 months follow-up</td>
<td>Randomised, open label, superiority, 24 months follow-up</td>
</tr>
<tr>
<td>Control group induction regimen</td>
<td>Oral CYC for 3–6 months High-dose glucocorticoids, tapered then withdrawn at 6 months</td>
<td>IV CYC for 3–6 months High-dose glucocorticoids, tapered to 5 mg prednisolone at 6 months</td>
</tr>
<tr>
<td>RTX group induction regimen</td>
<td>RTX 375 mg/m² × 4 High-dose glucocorticoids, tapered then withdrawn at 6 months</td>
<td>RTX 375 mg/m² × 4 2 doses IV CYC High-dose glucocorticoids, tapered to 5 mg prednisolone at 6 months</td>
</tr>
<tr>
<td>Control group maintenance regimen</td>
<td>Oral azathioprine</td>
<td>Oral azathioprine Low-dose glucocorticoids</td>
</tr>
<tr>
<td>RTX group maintenance regimen</td>
<td>None</td>
<td>Low-dose glucocorticoids</td>
</tr>
<tr>
<td>Plasma exchange usage</td>
<td>Not permitted</td>
<td>Optional use permitted</td>
</tr>
<tr>
<td>Primary remission endpoint</td>
<td>Remission at 6 months (with adherence to glucocorticoid withdrawal)</td>
<td>Remission sustained for 6 months by 12 months</td>
</tr>
</tbody>
</table>

Population characteristics

<table>
<thead>
<tr>
<th>Patients</th>
<th>197 (99 RTX, 98 CYC)</th>
<th>44 (33 RTX, 11 CYC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAV subtype</td>
<td>GPA 148 (75%) MPA 48 (25%)</td>
<td>GPA 22 (50%) MPA 16 (36%) Renal limited vasculitis 6 (14%)</td>
</tr>
<tr>
<td>New/relapsing disease</td>
<td>New disease 96 (48%) Relapsing disease 101 (52%)</td>
<td>New disease 44 (100%)</td>
</tr>
<tr>
<td>Renal vasculitis</td>
<td>130 (66%) Excluded if creatinine &gt;354 μmol/l</td>
<td>44 (100%) No renal exclusion criteria</td>
</tr>
<tr>
<td>Dialysis requirement at entry</td>
<td>0 (0%)</td>
<td>9 (20%)</td>
</tr>
<tr>
<td>ANCA positive at entry</td>
<td>196 (99%)</td>
<td>44 (100%)</td>
</tr>
</tbody>
</table>

Key outcomes

| Primary remission endpoint            | 63 (64%) RTX, 52 (53%) CYC Remission in patients with relapsing disease: 34 (67%) RTX, 21 (42%) CYC | 25 (76%) RTX, 9 (82%) CYC |
| Relapses at trial end                 | Severe relapses 27 (27%) RTX, 24 (24%) CYC Limited relapses 20 (20%) RTX, 21 (21%) CYC | All relapses 7 (21%) RTX, 2 (18%) CYC |
| Infections at trial end               | Severe infections 22 (12%) RTX, 11 (11%) CYC | Serious infections 11 (33%) RTX, 2 (18%) CYC |
| Mortality at trial end                | 2 (2%) RTX, 2 (2%) CYC | 6 (18%) RTX, 3 (27%) CYC |

Results are expressed as numbers and percentages. RTX = Rituximab; CYC = cyclophosphamide.
relapses were observed in patients who did not undergo re-treatment. Other investigators have found B cells and ANCA insufficiently reliable as relapse predictors, perhaps partly due to the treatment of more ANCA-negative patients [17]. An alternative remission maintenance approach is re-dosing with rituximab at fixed time intervals. Both 4-month [38] and 6-month [28] dosing intervals have been used [39], with low relapse rates observed. Consequently, rituximab maintenance strategies are now being evaluated in randomised trials. For relapsing AAV, the RITAZAREM trial is comparing 1,000 mg rituximab every 4 months to azathioprine, after rituximab induction therapy (1,000 mg × 2; NCT01697267). In newly diagnosed AAV, there is scope to improve the 50% 5-year relapse rate observed following standard cyclophosphamide induction and azathioprine maintenance regimens. The role of rituximab maintenance therapy after cyclophosphamide induction in newly diagnosed AAV has been evaluated by the MAINRITSAN trial (NCT00748644). 500 mg of rituximab every 6 months was compared to azathioprine. Results found a lower relapse rate in rituximab patients: 5% versus 29% at 2 years [40]. A further trial has been proposed to compare two rituximab 500 mg dosing strategies: either dosing every 6 months or re-treatment based on B cell and ANCA return (MAINRITSAN 2; NCT01731561).

The optimal duration of rituximab maintenance therapy is unknown. Uncontrolled studies and randomised trials have used a 2-year rituximab re-dosing regimen, followed by rituximab withdrawal and observation for relapse [28, 40, NCT01697267]. Initial data suggests that time to relapse is longer after a 2-year rituximab course than a single treatment course [28]. Withdrawal of rituximab at 2 years may therefore prove to be a reasonable approach. However, further outcome data is awaited to substantiate this.

### Safety of Rituximab in AAV

Overall, rituximab appears to be well tolerated in AAV. Neither the RAVE nor the RITUXVAS trial raised specific safety concerns with rituximab, although patient numbers were low. Further rituximab safety data is drawn from uncontrolled AAV cohorts and studies in rheumatoid arthritis and oncology indications.

In AAV, infusion reactions with rituximab are usually mild. However, potentially fatal infusion reactions can occur, but are very rare. Therefore, premedication with paracetamol, antihistamine and 100 mg methylprednisolone is recommended prior to each infusion [41].

Infection risk with rituximab has not been fully quantified in AAV. Notably, neither the RAVE nor the RITUXVAS trial found infections to be lower in the rituximab versus cyclophosphamide groups. Rituximab depletes the precursors to antibody-producing cells and is associated with significant falls in IgM within 3–6 months of use [19]. In relapsing patients, IgG levels are often low before rituximab, reflecting prior immunosuppression.

### Table 2. Rituximab remission maintenance studies in AAV

<table>
<thead>
<tr>
<th>Study author</th>
<th>Study design</th>
<th>Patient number</th>
<th>Rituximab maintenance protocol</th>
<th>Proportion with relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhee et al. [38]</td>
<td>retrospective</td>
<td>39</td>
<td>1,000 mg every 4 months</td>
<td>7.6% after 18 months (mean)</td>
</tr>
<tr>
<td>Smith et al. [28]</td>
<td>retrospective</td>
<td>64 (group B: 45; group C: 19)</td>
<td>1,000 mg every 6 months for 2 years</td>
<td>12% group B 11% group C</td>
</tr>
<tr>
<td>Cartin-Ceba et al. [29]</td>
<td>retrospective</td>
<td>53</td>
<td>4 doses of 375 mg/m² (90%) 2 doses of 1,000 mg (10%) based on B cell and ANCA criteria</td>
<td>0% in patients re-treated at 4.4 years (median) (NB 32 relapses occurred in patients not re-treated)</td>
</tr>
<tr>
<td>Roubaud-Baudron et al. [39]</td>
<td>retrospective</td>
<td>28</td>
<td>375 mg/m² every 6 months, n = 14 1,000 mg every 6 months, n = 4 1,000 mg every 12 months, n = 3 Other regimens, n = 7</td>
<td>7% at 38 months (median)</td>
</tr>
<tr>
<td>Guillevin et al. [40]</td>
<td>randomised trial</td>
<td>58 rituximab</td>
<td>500 mg every 6 months for 2 years 59 azathioprine</td>
<td>5% rituximab 29% azathioprine</td>
</tr>
</tbody>
</table>

---

Rituximab in the Treatment of AAV


DOI: 10.1159/000368580
exposure [42]. Following rituximab, transient falls in IgG are frequent and a minority develop sustained severe hypogammaglobulinaemia [42, 43]. Prior cyclophosphamide exposure and ongoing glucocorticoids may contribute to hypogammaglobulinaemia following rituximab. Monitoring IgG can be helpful to differentiate transient from sustained hypogammaglobulinaemia, particularly in patients with recurrent infections. Moderate or severe hypogammaglobulinaemia complicated by recurrent infection is an indicator to consider rituximab withdrawal and IgG replacement therapy.

Other potentially fatal infective complications include progressive multifocal leucoencephalopathy following JC virus reactivation, and fulminant liver failure due to hepatitis B reactivation. Progressive multifocal leucoencephalopathy in rituximab–treated patients is very rare, but fatal, so physicians and patients should be aware of the risk. Patients should be screened for hepatitis B prior to rituximab to exclude active infection or prior exposure. In patients with prior exposure, lamivudine prophylaxis is recommended. Rituximab should be avoided in patients with prior exposure and ongoing glucocorticoids may contribute to hypogammaglobulinaemia associated with ongoing glucocorticoids. In patients at risk of malignancy, rituximab may be considered preferable to cyclophosphamide, which has well-established malignancy risks. In AAV, long-term malignancy data with rituximab is not available. In rheumatoid arthritis, malignancies are not increased by the addition of rituximab to methotrexate [45]. In oncology, however, more solid organ malignancies were reported during 5–10 years of follow-up after rituximab with chemotherapy compared to chemotherapy alone [46].

Conclusions

Rituximab has been used to treat AAV for more than 10 years. Randomised trials investigating rituximab for remission induction have been performed. Rituximab is now an approved alternative to cyclophosphamide for remission induction, and is increasingly used to treat patients with relapsing or refractory disease. Relapse rates are high after rituximab in relapsing AAV. However, repeat dosing is effective and consequently rituximab maintenance strategies have evolved. Remission maintenance trials comparing rituximab to azathioprine are underway, and provisional results are promising. Areas for further investigation include remission maintenance therapy requirements in newly diagnosed patients treated with rituximab induction therapy, optimal dosing and duration of rituximab for remission maintenance, and the efficacy of rituximab for EGPA.

Disclosure Statement

Dr. Jones undertook a part-time academic secondment to GlaxoSmithKline from 2011 to 2013.

References

Rituximab in the Treatment of AAV

DOI: 10.1159/000368580


